Please assess the completion status of the following clinical trial:

Trial Title: Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate pre-transplant renal dysfunction as defined serum creatinine levels higher than 1.5 mg/dl or eGFR (MDRD-4) \<60ml/min.~* First liver transplant, including splits liver transplant.~* Patients aged 18-70 years~* Without a prior contraindication for protocol biopsy of allograft.~Exclusion Criteria:~* Multiorgan transplantation and/or liver transplant from DCD and/or with ABO incompatibility.~* Uncontrolled concomitant infections (including HIV seropositivity) and/or diarrhoea, vomiting or active gastric ulcer.~* Fulminant hepatic insufficiency as first indication for liver transplant~* Hemodynamic instability prior to liver transplant.~* Recipient presenting present or previous neoplasia, except for non-metastatic basal or squamous cutaneous carcinoma or localized hepatocarcinoma with diameter \<5 cm or \< 3 known lesions with diameter \<3 cm.~* Intolerance to study medication.~* Patients having received vaccination with attenuated living vaccines within the previous 4 weeks.~* Severe leukopenia (\< 1.2 X 10E9/L) and/or thrombocytopenia (\< 50x10E9/L) and/or lymphocyte counts (CD2+/CD3+) less than 10 cells/µl.~* Significant comorbidity.~* Breastfeeding or female patients at fertile age without negative pregnancy test and accepting the use of reliable fertility control method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Basiliximab (Type: NO_INTERVENTION): Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
- ATeGe-Fresenius (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).